Fatimah. Abushoumi

In 1975, Georges Kohler of West Germany and Cesar Milstein of Argentina discovered how to produce monoclonal antibodies (MAbs) utilizing hybridoma technology. Since the US Food and Drug Administration (US FDA) approved the first monoclonal antibody in 1986, more than three decades have passed, and a significant advancement in antibody engineering has been made. Marketing approval has been given to over 100 mAbs so far. Although MAb therapies are mostly used to treat cancer and immunological/infectious illnesses, they are also being used to treat other types of diseases like arthritis and other conditions brought on by organ transplantation and have many uses in applied biology, biotechnology, and biochemistry. MAbs have more uses today than ever before, according to research being conducted in labs all over the world. It is anticipated that the therapeutic pipeline will continue to include the several monoclonal antibodies that are now in research due to their distinct characteristics. Therapeutic monoclonal antibodies have drawn a lot more attention in recent years. The development of a new generation of therapeutic drugs is made possible by the advent of molecular targeting medicine. Their extremely specific target of antigens can result in very successful medical treatment. This review examines cutting-edge technology relevant to the future prospects of MAbs and highlights the therapeutic applications of MAbs.